Cero Therapeutics removed from Nasdaq for failing continued-listing standards
Nasdaq delisted Cero Therapeutics Holdings, Inc.'s common stock and warrants on July 13, 2026, under Rule 17 CFR 240.12d2-2(b) for failure to meet continued-listing standards. The removal was exchange-initiated and represents an adverse listing determination.
Key facts
- Nasdaq delisted Cero Therapeutics Holdings, Inc. common stock and warrants on July 13, 2026
- Delisting basis: Rule 17 CFR 240.12d2-2(b) — failure to meet continued-listing standards
- Removal initiated by exchange, not orderly acquisition or merger mechanics
Why it matters
Cero Therapeutics is no longer eligible for trading on Nasdaq and must cease exchange listing; shareholders lose liquidity and the company faces the operational and reputational consequences of delisting.
Share
Derived from 25-NSE filed 2026-07-13. Not investment advice. View the source filing on SEC.gov →